We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01020890
First Posted: November 26, 2009
Last Update Posted: July 12, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
November 25, 2009
November 26, 2009
July 12, 2010
November 2009
April 2010   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01020890 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms
A Cross-sectional Study on the Prevalence of GERD in Primary Care Patients With Upper GI Symptoms Using the GERD-Q. The Bulgarian GERD-Q Study
The purpose of this study is to provide data on the gastroesophageal reflux disease (GERD) prevalence as percentage of patients with upper gastrointestinal (GI) symptoms that are identified with GERD using the Gerd-Q Questionnaire.
Not Provided
Observational
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample
Primary care clinic
Gastroesophageal Reflux Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2210
April 2010
April 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with upper gastrointestinal symptoms

Exclusion Criteria:

  • History of oesophageal, gastric or duodenal surgery
  • Current treatment with antiinflammatory drugs, including OTC
  • Current treatment with proton pump inhibitors ang H2-blockers
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Bulgaria
 
 
NCT01020890
NIS-GBG-NEX-2009/1
No
Not Provided
Not Provided
MC MD, AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
July 2010